GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

WASHINGTON — Pharmaceutical industry giant GSK plans to depart the biotechnology industry’s largest trade group, the ...

Phenylephrine is widely used in a variety of over-the-counter flu and cold medicines, including popular products such as Benadryl ... the ingredient Companies such as Procter & Gamble and GSK were ...

"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product ... GSK opened 1.9-percent lower in London following the results update. Over-the ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

Since taking the helm of GSK in 2017, Walmsley has returned the company to growth with a focus on cancer and infectious diseases to counter a combination ... a new shadow over the shares.